Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis

被引:6
|
作者
McLinden, Taylor [1 ]
Moodie, Erica E. M. [1 ]
Hamelin, Anne-Marie [1 ]
Harper, Sam [1 ]
Rossi, Carmine [1 ]
Walmsley, Sharon L. [2 ,3 ]
Rourke, Sean B. [4 ,5 ,6 ]
Cooper, Curtis [7 ]
Klein, Marina B. [8 ,9 ]
Cox, Joseph [1 ,8 ,9 ]
机构
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, 1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ Hlth Network, Div Infect Dis, Toronto, ON, Canada
[4] Ontario HIV Treatment Network, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[8] McGill Univ, Ctr Hlth, Chron Viral Illness Serv, Montreal, PQ, Canada
[9] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada
基金
加拿大健康研究院;
关键词
Methadone treatment; Severe food insecurity; HIV; Hepatitis C virus; Propensity score matching; INFECTED INDIVIDUALS; C VIRUS; PREVALENCE; PEOPLE;
D O I
10.1016/j.drugalcdep.2017.12.031
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Severe food insecurity (FI) is common among individuals living with HIV-hepatitis C virus (HCV) co-infection. We hypothesize that the injection of opioids is partly responsible for the association between injection drug use and severe FI. Therefore, this analysis examines whether methadone maintenance treatment for opioid dependence is associated with a lower risk of severe Fl. Methods: We used biannual data from the Canadian Co-infection Cohort (N = 608, 2012-2015). Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module. To quantify the association between methadone treatment and severe FI, we estimated an average treatment effect on the treated (marginal risk difference [RD]) using propensity score matching. Results: Among participants, 25% experienced severe FI in the six months preceding the first time-point in the analytical sample and 5% concurrently reported receiving methadone treatment. Injection of opioids in the six months preceding the treatment and outcome measurements was much higher among those who received methadone treatment (39% vs. 12%). Among the treated participants, 97% had injected opioids in their lifetimes. After propensity score matching, the average risk of experiencing severe FI is 12.3 percentage-points lower among those receiving methadone treatment, compared to those who are not receiving treatment (marginal RD = -0.123, 95% CI = -0.230, 0.015). Conclusions: After adjustment for socioeconomic, sociodemographic, behavioural, and clinical confounders, methadone treatment is associated with a lower risk of severe FI. This finding suggests that methadone treatment may mitigate severe FI in this vulnerable subset of the HIV-positive population.
引用
收藏
页码:374 / 380
页数:7
相关论文
共 50 条
  • [31] HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection
    Audsley, Jennifer
    du Cros, Philipp
    Goodman, Zachary
    McLean, Catriona
    Mijch, Anne
    Lewin, Sharon R.
    Sasadeusz, Joe
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (07) : 993 - 1001
  • [32] Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision
    Cooper, Curtis L.
    Giordano, Celine
    Mackie, Dave
    Mills, Edward J.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 207 - 212
  • [33] Factors participating in severe HCV-related liver disease in HIV/HCV co-infection
    Lapoile, E
    Vona, G
    Canioni, D
    Chaix, ML
    Nalpas, B
    Fontaine, H
    Brechot, C
    Pol, S
    JOURNAL OF HEPATOLOGY, 2002, 36 : 172 - 172
  • [34] Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection
    Ragni, M. V.
    Nalesnik, M. A.
    Schillo, R.
    Dang, Q.
    HAEMOPHILIA, 2009, 15 (02) : 552 - 558
  • [35] Treatment of acute HCV infection in HIV co-infection: Influence of HCV genotype and ribavirin upon treatment outcome
    Boesecke, Christoph
    Ingiliz, Patrick
    Stellbrink, Hans-Juergen
    Nelson, Mark
    Page, Emma E.
    Bhagani, Sanjay
    Guiguet, Marguerite
    Valantin, Marc-Antoine
    Reiberger, Thomas
    Vogel, Martin
    Rockstroh, Juergen K.
    HEPATOLOGY, 2012, 56 : 215A - 215A
  • [36] Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome
    Christoph Boesecke
    Patrick Ingiliz
    Thomas Reiberger
    Hans-Jürgen Stellbrink
    Sanjay Bhagani
    Emma Page
    Stefan Mauss
    Thomas Lutz
    Esther Voigt
    Marguerite Guiguet
    Marc-Antoine Valantin
    Axel Baumgarten
    Mark Nelson
    Martin Vogel
    Jürgen K. Rockstroh
    Infection, 2016, 44 : 93 - 101
  • [37] Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome
    Boesecke, Christoph
    Ingiliz, Patrick
    Reiberger, Thomas
    Stellbrink, Hans-Juergen
    Bhagani, Sanjay
    Page, Emma
    Mauss, Stefan
    Lutz, Thomas
    Voigt, Esther
    Guiguet, Marguerite
    Valantin, Marc-Antoine
    Baumgarten, Axel
    Nelson, Mark
    Vogel, Martin
    Rockstroh, Jurgen K.
    INFECTION, 2016, 44 (01) : 93 - 101
  • [38] HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection
    Denholm, J. T.
    Wright, E. J.
    Street, A.
    Sasadeusz, J. J.
    HAEMOPHILIA, 2009, 15 (02) : 538 - 543
  • [39] HIV and HCV:from Co-infection to Epidemiology,Transmission,Pathogenesis,and Treatment
    Lei KANG1
    2. College of Life Sciences
    Virologica Sinica, 2007, (06) : 443 - 450
  • [40] Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV
    Smith, Anton A. A.
    Zuwala, Kaja
    Kryger, Mille B. L.
    Wohl, Benjamin M.
    Guerrero-Sanchez, Carlos
    Tolstrup, Martin
    Postma, Almar
    Zelikin, Alexander N.
    CHEMICAL SCIENCE, 2015, 6 (01) : 264 - 269